Literature DB >> 14642699

Time course of the interaction between tadalafil and nitrates.

Robert A Kloner1, Adolph M Hutter, Jeffrey T Emmick, Malcolm I Mitchell, Jonathan Denne, Graham Jackson.   

Abstract

OBJECTIVES: This study was designed to determine the time course of nitrate interaction with tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t(1/2)) of 17.5 h.
BACKGROUND: The PDE5 inhibitors augment the blood pressure (BP)-lowering effects of nitrates, yet the time course of this interaction is unclear. Recent guidelines from the American College of Cardiology/American Heart Association recommend that nitrates be withheld for 24 h after taking sildenafil (t(1/2) = 4 h).
METHODS: Male subjects (n = 150) received seven consecutive daily doses of placebo or tadalafil (20 mg). On day 7 and beyond, subjects received repeated doses of sublingual nitroglycerin (0.4 mg) after the last dose of placebo or tadalafil. After a 10- to 21-day washout period, subjects crossed over to either placebo or tadalafil, and nitrate dosing was repeated.
RESULTS: In response to nitroglycerin at 4, 8, and 24 h, standing systolic BP fell below 85 mm Hg in more subjects on tadalafil compared with placebo (p < 0.05), with no difference in the response to nitroglycerin at 48, 72, and 96 h (p > 0.2). Similar observations were made for standing diastolic BP <45 mm Hg, decrease in systolic BP >30 mm Hg, and decrease in diastolic BP >20 mm Hg. Nitroglycerin also evoked greater mean maximal decreases in standing systolic BP at 8 and 24 h after taking tadalafil versus placebo (p < 0.02), with no significant difference at 48, 72, or 96 h (p > 0.49).
CONCLUSIONS: The hemodynamic interaction between tadalafil and sublingual nitroglycerin lasted 24 h, but was not seen at 48 h and beyond. Similar to other PDE5 inhibitors, tadalafil should not be administered in combination with organic nitrates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642699     DOI: 10.1016/j.jacc.2003.09.023

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

Review 1.  Beta-blocker administration protocol for prospectively ECG-triggered coronary CT angiography.

Authors:  Akmal Sabarudin; Zhonghua Sun
Journal:  World J Cardiol       Date:  2013-12-26

Review 2.  Sexual activity and ischemic heart disease.

Authors:  Richard A Lange; Glenn N Levine
Journal:  Curr Cardiol Rep       Date:  2014-02       Impact factor: 2.931

3.  Survivorship: sexual dysfunction (male), version 1.2013.

Authors:  Crystal S Denlinger; Robert W Carlson; Madhuri Are; K Scott Baker; Elizabeth Davis; Stephen B Edge; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Elizabeth Kvale; Terry S Langbaum; Jennifer A Ligibel; Mary S McCabe; Kevin T McVary; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Tracey O'Connor; Electra D Paskett; Muhammad Raza; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole McMillian; Deborah Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2014-03-01       Impact factor: 11.908

Review 4.  Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.

Authors:  Alberto Briganti; Andrea Salonia; Federico Deho'; Giuseppe Zanni; Luigi Barbieri; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2005-11-05       Impact factor: 4.226

Review 5.  Phosphodiesterase-5 inhibitors and their hemodynamic effects.

Authors:  L Michael Prisant
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

6.  Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Crystal S Denlinger; Tara Sanft; K Scott Baker; Shrujal Baxi; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Elizabeth Kvale; Robin M Lally; Terry S Langbaum; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Deborah A Freedman-Cass; Nicole R McMillian
Journal:  J Natl Compr Canc Netw       Date:  2017-09       Impact factor: 11.908

Review 7.  Management of erectile dysfunction in hypertension: Tips and tricks.

Authors:  Margus Viigimaa; Charalambos Vlachopoulos; Antonios Lazaridis; Michael Doumas
Journal:  World J Cardiol       Date:  2014-09-26

Review 8.  Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.

Authors:  Sharon A Huang; Janette D Lie
Journal:  P T       Date:  2013-07

Review 9.  The use of phosphodiesterase 5 inhibitors with concomitant medications.

Authors:  G Corona; E Razzoli; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

Review 10.  Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.

Authors:  H Al-Ameri; R A Kloner
Journal:  Int J Impot Res       Date:  2009-04-23       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.